GSK Buys CureVac Out Of Jointly Developed mRNA Influenza, COVID-19 Vaccines

Reuters (7/3, Fick, Weiss, Burger, Shabong) reported, “British drugmaker GSK on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the German biotech company’s financial lifeline.” As a result, GSK “will take control of CureVac’s leading experimental vaccines to fight infections, including seasonal flu and bird flu. It will pay CureVac 400 million euros ($430 million) upfront and up to 1.05 billion euros contingent on achievements.”